Vanguard Capital Management
CLB icon

Vanguard Capital Management’s Core Laboratories CLB Stock Holding History

Vanguard Capital Management’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.5M Sell
1,590,521
-29,342
-2% -$419K ﹤0.01% 2484
2026
Q1 		$27.2M Buy
+1,619,863
New +$29M ﹤0.01% 2180

Other funds holding CLB

AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management's CLB Position: Q2 2026 in Review

Vanguard Capital Management reduced its Core Laboratories (CLB) stake by 1.8% in Q2 2026, selling an estimated $419K and leaving 1,590,521 shares worth $18.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2484.

Vanguard Capital Management first reported a position in CLB in Q1 2026 and has held it in 2 quarters since. The position peaked at $27.2M in Q1 2026. 185 funds tracked by Wall St. Rank hold CLB as of Q2 2026.

  • Vanguard Capital Management held 1,590,521 shares of Core Laboratories worth $18.5M as of Q2 2026.
  • Vanguard Capital Management sold 29,342 Core Laboratories shares in Q2 2026, an estimated $419K.
  • Core Laboratories made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2484 holding.
  • Vanguard Capital Management first reported a position in Core Laboratories in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Core Laboratories position peaked at $27.2M in Q1 2026.
  • 185 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.